Artiva Biotherapeutics (NASDAQ:ARTV) Price Target Cut to $20.00 by Analysts at Cantor Fitzgerald

Artiva Biotherapeutics (NASDAQ:ARTV) had its price objective trimmed by Cantor Fitzgerald from $23.00 to $20.00 in a report issued on Tuesday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

Several other analysts have also recently commented on the stock. HC Wainwright began coverage on shares of Artiva Biotherapeutics in a research note on Monday, December 30th. They issued a “buy” rating and a $20.00 price target on the stock. Wedbush reiterated an “outperform” rating and issued a $18.00 target price on shares of Artiva Biotherapeutics in a research report on Tuesday. Finally, Needham & Company LLC restated a “buy” rating and set a $23.00 price target on shares of Artiva Biotherapeutics in a report on Tuesday. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $20.40.

Artiva Biotherapeutics Stock Performance

ARTV opened at $3.99 on Tuesday. The firm’s fifty day moving average is $4.91 and its 200 day moving average is $9.37. Artiva Biotherapeutics has a fifty-two week low of $3.37 and a fifty-two week high of $17.31.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several large investors have recently added to or reduced their stakes in ARTV. State Street Corp purchased a new position in shares of Artiva Biotherapeutics in the 3rd quarter worth approximately $1,337,000. Geode Capital Management LLC bought a new stake in Artiva Biotherapeutics in the third quarter worth $4,774,000. Barclays PLC purchased a new position in Artiva Biotherapeutics during the third quarter worth $304,000. BNP Paribas Financial Markets bought a new position in Artiva Biotherapeutics during the third quarter valued at $42,000. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Artiva Biotherapeutics in the third quarter valued at $166,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.